Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 610
Filter
Add more filters

Complementary Medicines
Publication year range
1.
Fitoterapia ; 172: 105739, 2024 Jan.
Article in English | MEDLINE | ID: mdl-37952763

ABSTRACT

In this study, 30 chalcone derivatives containing [1,2,4]-triazole-[4,3-a]-pyridine were designed and synthesized. The results of antibacterial activity showed that EC50 values of N26 against Xoo, Pcb was 36.41, 38.53 µg/mL, respectively, which were better than those of thiodiazole copper, whose EC50 values were 60.62, 106.75 µg/mL, respectively. The bacterial inhibitory activity of N26 against Xoo was verified by SEM. Antibacterial mechanism between N26 and Xoo was preliminarily explored, the experimental results showed that when the drug concentration was 100 mg/L, N26 had a good cell membrane permeability of Xoo, and it can inhibit the production of EPS content and extracellular enzyme content to disrupt the integrity of the Xoo biofilms achieving the effect of inhibiting Xoo. At 200 mg/L, N26 can protect and inhibit the lesions of post-harvested potatoes in vivo. The activities of N1-N30 against TMV were determined with half leaf dry spot method. The EC50 values of the curative and protective activity of N22 was 77.64 and 81.55 µg/mL, respectively, which were superior to those of NNM (294.27, 175.88 µg/mL, respectively). MST experiments demonstrated that N22 (Kd = 0.0076 ± 0.0007 µmol/L) had a stronger binding ability with TMV-CP, which was much higher than that of NNM (Kd = 0.7372 ± 0.2138 µmol/L). Molecular docking results showed that N22 had a significantly higher affinity with TMV-CP than NNM.


Subject(s)
Chalcone , Chalcones , Oryza , Xanthomonas , Chalcone/pharmacology , Chalcones/pharmacology , Molecular Structure , Molecular Docking Simulation , Triazoles/pharmacology , Microbial Sensitivity Tests , Pyridines/pharmacology , Anti-Bacterial Agents/pharmacology , Plant Diseases , Oryza/microbiology , Structure-Activity Relationship , Drug Design
2.
Science ; 380(6652): 1349-1356, 2023 06 30.
Article in English | MEDLINE | ID: mdl-37384702

ABSTRACT

Millions who live in Latin America and sub-Saharan Africa are at risk of trypanosomatid infections, which cause Chagas disease and human African trypanosomiasis (HAT). Improved HAT treatments are available, but Chagas disease therapies rely on two nitroheterocycles, which suffer from lengthy drug regimens and safety concerns that cause frequent treatment discontinuation. We performed phenotypic screening against trypanosomes and identified a class of cyanotriazoles (CTs) with potent trypanocidal activity both in vitro and in mouse models of Chagas disease and HAT. Cryo-electron microscopy approaches confirmed that CT compounds acted through selective, irreversible inhibition of trypanosomal topoisomerase II by stabilizing double-stranded DNA:enzyme cleavage complexes. These findings suggest a potential approach toward successful therapeutics for the treatment of Chagas disease.


Subject(s)
Chagas Disease , Topoisomerase II Inhibitors , Triazoles , Trypanosoma , Trypanosomiasis, African , Animals , Humans , Mice , Chagas Disease/drug therapy , Cryoelectron Microscopy , DNA Topoisomerases, Type II/metabolism , Trypanosoma/drug effects , Topoisomerase II Inhibitors/chemistry , Topoisomerase II Inhibitors/pharmacology , Topoisomerase II Inhibitors/therapeutic use , Triazoles/chemistry , Triazoles/pharmacology , Triazoles/therapeutic use , Trypanosomiasis, African/drug therapy , Drug Evaluation, Preclinical
3.
Chem Biol Interact ; 370: 110312, 2023 Jan 25.
Article in English | MEDLINE | ID: mdl-36535312

ABSTRACT

In this study, eight new compounds (7a-h) based on triazole compounds containing ester groups were synthesized with high yields. The structures of the synthesized compounds (7a-h) were elucidated by various spectroscopic methods (element analysis, FT-IR, 1H-(13C) NMR). Antioxidant, anticancer, and α-amylase enzyme inhibition activities of synthesized new triazole derivatives were carried out, and the effects of different groups on the activity were investigated. When the determined antioxidant properties of the compounds were examined, all synthesized compounds showed a moderate radical scavenging effect against radicals depending on the concentration (6.25-200 g/mL). All compounds except the three derivatives were found to have higher IC50 values than the standard drug acarbose (IC50: 891 µg/mL) according to the α-amylase enzyme inhibition results. Compound 7g (IC50: 50 g/mL) was discovered to have nearly eighteen (18) times the activity of the conventional medication acarbose (IC50: 891 µg/mL). Compounds synthesized for anticancer activity studies were screened against the Hela cell line, and the results were compared with standard cis-platinum (IC50: 16.30 µg/mL). Compound 7g (IC50: 19.78 µg/mL) was found to have almost the same activity as cis-platinum. Using Qikprop, the compounds were thoroughly tested for ADME qualities, and none violated any drug similarity standards. According to ADME data, whole physicochemical drug-likeness parameters of molecules remained within defined ranges as stipulated in the Lipinski rules (RO5) and revealed a high bioavailability profile. The molecular docking results with 2QV4 and 4GQR alpha-amylase enzymes demonstrated that all molecules have a high affinity, indicating polar and apolar interaction with critical amino acids in the α-amylase binding pocket.


Subject(s)
Acarbose , Antioxidants , Humans , Molecular Docking Simulation , Structure-Activity Relationship , Antioxidants/pharmacology , HeLa Cells , Cisplatin , Triazoles/pharmacology , Triazoles/chemistry , Spectroscopy, Fourier Transform Infrared , alpha-Amylases/metabolism , Molecular Structure
4.
Bioorg Med Chem Lett ; 78: 129044, 2022 12 15.
Article in English | MEDLINE | ID: mdl-36336315

ABSTRACT

In this work, a series of novel 1,2,4-triazole derivatives with selenium-containing hydrophobic side chains were designed and synthesized based on the structure of lanosterol 14α-demethylase (CYP51). All compounds were characterized by HRMS, 1H NMR and 13C NMR. Then, their antifungal activities against eight human pathogenic fungi were evaluated in vitro by testing the minimal inhibitory concentrations. The results showed that nearly all tested compounds were found to be more potent against all tested fungal strains than control drug fluconazole. Further mechanism study demonstrated that the target compounds had fungal CYP51 inhibitory activity. Meanwhile, representative compounds revealed low cytotoxic effects toward mammalian cell lines. In addition, the docking results showed that the target compounds bound to Candida albicans CYP51 in a better pattern than fluconazole, especially in the narrow hydrophobic cleft. Overall, the novel 1,2,4-triazole derivatives with selenium-containing hydrophobic side chains can be further developed for the potential treatment of invasive fungal infections.


Subject(s)
Invasive Fungal Infections , Selenium , Humans , Animals , Antifungal Agents/pharmacology , Selenium/pharmacology , Fluconazole , Triazoles/pharmacology , Mammals
5.
Bioorg Med Chem Lett ; 61: 128590, 2022 04 01.
Article in English | MEDLINE | ID: mdl-35108623

ABSTRACT

Neuraminidase (NA) is an ideal target for the development of anti-influenza drugs. In this paper, ZINC06057848 was screened out as a hit compound by docking-based virtual screening and molecular dynamics (MD) simulation. The modification and optimization of hit ZINC06057848 resulted in the discovery of a series of novel 1,3,4-triazole-containing NA inhibitors (5a-5j). Compound 5c exerts the best inhibitory activity (IC50 = 0.11 µM) against NA, which is comparable to the positive control oseltamivir carboxylate (OSC) (IC50 = 0.10 µM). Molecular docking analysis indicates that the good efficacy of inhibitor 5c may be attributed to the furan and triazole rings extending into 430-cavity and the ethylbenzene part occupying the active site. The results of this work may help in the development of new NA inhibitors.


Subject(s)
Acetamides/pharmacology , Drug Design , Enzyme Inhibitors/pharmacology , Neuraminidase/antagonists & inhibitors , Triazoles/pharmacology , Acetamides/chemical synthesis , Acetamides/chemistry , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/chemistry , Humans , Molecular Structure , Neuraminidase/metabolism , Structure-Activity Relationship , Triazoles/chemical synthesis , Triazoles/chemistry
6.
PLoS Negl Trop Dis ; 16(2): e0010159, 2022 02.
Article in English | MEDLINE | ID: mdl-35120131

ABSTRACT

Eumycetoma is a chronic subcutaneous neglected tropical disease that can be caused by more than 40 different fungal causative agents. The most common causative agents produce black grains and belong to the fungal orders Sordariales and Pleosporales. The current antifungal agents used to treat eumycetoma are itraconazole or terbinafine, however, their cure rates are low. To find novel drugs for eumycetoma, we screened 400 diverse drug-like molecules from the Pandemic Response Box against common eumycetoma causative agents as part of the Open Source Mycetoma initiative (MycetOS). 26 compounds were able to inhibit the growth of Madurella mycetomatis, Madurella pseudomycetomatis and Madurella tropicana, 26 compounds inhibited Falciformispora senegalensis and seven inhibited growth of Medicopsis romeroi in vitro. Four compounds were able to inhibit the growth of all five species of fungi tested. They are the benzimidazole carbamates fenbendazole and carbendazim, the 8-aminoquinolone derivative tafenoquine and MMV1578570. Minimal inhibitory concentrations were then determined for the compounds active against M. mycetomatis. Compounds showing potent activity in vitro were further tested in vivo. Fenbendazole, MMV1782387, ravuconazole and olorofim were able to significantly prolong Galleria mellonella larvae survival and are promising candidates to explore in mycetoma treatment and to also serve as scaffolds for medicinal chemistry optimisation in the search for novel antifungals to treat eumycetoma.


Subject(s)
Antifungal Agents/pharmacology , Drug Evaluation, Preclinical , Mycetoma/drug therapy , Acetamides/pharmacology , Animals , Ascomycota/drug effects , Drug Discovery , Fenbendazole/pharmacology , Madurella/drug effects , Moths/microbiology , Neglected Diseases , Piperazines/pharmacology , Pyrimidines/pharmacology , Pyrroles/pharmacology , Thiazoles/pharmacology , Triazoles/pharmacology
7.
Biotechnol Prog ; 38(1): e3206, 2022 01.
Article in English | MEDLINE | ID: mdl-34460147

ABSTRACT

The application of biological nanoparticles (NPs) can be considered as a way to overcome the problem of antifungal resistance in pathogenic fungi. This study takes a new approach to biosynthesized NPs influence on the expression of CYP51A and HSP90 antifungal resistance genes in Aspergillus fumigatus and A. flavus, and comparison with antifungal agents. Selenium NPs (Se-NPs) were biosynthesized using Aspergillus strains and their production was proved by several methods including, UV-Vis, XRD, FTIR, FESEM, and EDX techniques. The minimum inhibitory concentrations (MICs) of Aspergillus strains were determined using the CLSI M38-A2 broth microdilution method. The differences in expression levels of CYP51A and HSP90 genes were examined between untreated and treated of A. fumigatus and A. flavus using itraconazole and amphotericin B and biosynthesized Se-NPs through real-time PCR. After confirming the results of NPs synthesis, the MIC of itraconazole and amphotericin B against A. fumigatus and A. flavus was 4 µg/ml. Based on the real-time PCR results, the obtained ∆∆CTs for these strains were -0.18, -1.46, and -1.14. Whereas the MIC values for treated samples with Se-NPs have decreased to 0.5 µg/ml, and the ∆∆CTs for these were -0.25, -1.76, and -1.68. The expression of CYP51A and HSP90 genes was significantly down-regulated through the use of Se-NPs against A. fumigatus and A. flavus.


Subject(s)
Nanoparticles , Selenium , Amphotericin B/pharmacology , Antifungal Agents/pharmacology , Aspergillus/genetics , Aspergillus flavus , Aspergillus fumigatus/genetics , Itraconazole/pharmacology , Microbial Sensitivity Tests , Selenium/pharmacology , Triazoles/pharmacology , Voriconazole/pharmacology
8.
Plant Dis ; 106(4): 1134-1142, 2022 Apr.
Article in English | MEDLINE | ID: mdl-34752126

ABSTRACT

Microbial communities are essential for soil health, but fungicide application may have significant effects on their structure. It is difficult to predict whether nontarget pathogens of applied fungicides in the soil will cause crop damage. Tebuconazole is a triazole fungicide that can be used as a seed treatment and, thereby, introduced to the soil. However, seed-applied tebuconazole has a potential risk of causing poor emergence of corn (Zea mays) seedlings. Using soil with a history of poor corn seedling emergence, we demonstrate through TA cloning and isolation that the poor emergence of corn seedlings from tebuconazole-coated corn seeds was primarily because of infection by surviving soil pathogens, specifically Pythium species that are not targeted by tebuconazole, rather than the phytotoxic effects of tebuconazole. Bioassay tests on tebuconazole-amended media showed that tebuconazole can suppress soil fungi while allowing Pythium to grow. Pythium species primarily contributing to the corn seed rot were more pathogenic at cooler temperatures. Furthermore, the nontarget biocontrol agent of Trichoderma spp. was strongly inhibited by tebuconazole. Taken together, the nontarget effects of tebuconazole are likely not significant under favorable plant growing conditions but are considerable because of low-temperature stress.


Subject(s)
Fungicides, Industrial , Pythium , Fungicides, Industrial/pharmacology , Prevalence , Seedlings , Seeds/microbiology , Soil , Triazoles/pharmacology , Zea mays
9.
Mar Drugs ; 19(12)2021 Nov 29.
Article in English | MEDLINE | ID: mdl-34940681

ABSTRACT

Marine biofouling is a natural process that represents major economic, environmental, and health concerns. Some booster biocides have been used in biofouling control, however, they were found to accumulate in environmental compartments, showing negative effects on marine organisms. Therefore, it is urgent to develop new eco-friendly alternatives. Phenyl ketones, such as benzophenones and acetophenones, have been described as modulators of several biological activities, including antifouling activity (AF). In this work, acetophenones were combined with other chemical substrates through a 1,2,3-triazole ring, a strategy commonly used in Medicinal Chemistry. In our approach, a library of 14 new acetophenone-triazole hybrids was obtained through the copper(I)-catalyzed alkyne-azide cycloaddition "click" reaction. All of the synthesized compounds were evaluated against the settlement of a representative macrofouling species, Mytilus galloprovincialis, as well as on biofilm-forming marine microorganisms, including bacteria and fungi. The growth of the microalgae Navicula sp. was also evaluated after exposure to the most promising compounds. While compounds 6a, 7a, and 9a caused significant inhibition of the settlement of mussel larvae, compounds 3b, 4b, and 7b were able to inhibit Roseobacter litoralis bacterial biofilm growth. Interestingly, acetophenone 7a displayed activity against both mussel larvae and the microalgae Navicula sp., suggesting a complementary action of this compound against macro- and microfouling species. The most potent compounds (6a, 7a, and 9a) also showed to be less toxic to the non-target species Artemia salina than the biocide Econea®. Regarding both AF potency and ecotoxicity activity evaluation, acetophenones 7a and 9a were put forward in this work as promising eco-friendly AF agents.


Subject(s)
Acetophenones/pharmacology , Biofouling/prevention & control , Disinfectants/pharmacology , Triazoles/pharmacology , Acetophenones/chemistry , Animals , Aquatic Organisms , Biofilms/drug effects , Bivalvia/drug effects , Disinfectants/chemistry , Larva/drug effects , Microalgae/drug effects , Structure-Activity Relationship , Triazoles/chemistry
10.
J Nanobiotechnology ; 19(1): 433, 2021 Dec 20.
Article in English | MEDLINE | ID: mdl-34930269

ABSTRACT

BACKGROUND: The construction of a nanoimmune controlled-release system that spatiotemporally recognizes tumor lesions and stimulates the immune system response step by step is one of the most potent cancer treatment strategies for improving the sensitivity of immunotherapy response. RESULTS: Here, a composite nanostimulator (CNS) was constructed for the release of second near-infrared (NIR-II) photothermal-mediated immune agents, thereby achieving spatiotemporally controllable photothermal-synergized immunotherapy. CNS nanoparticles comprise thermosensitive liposomes as an outer shell and are internally loaded with a NIR-II photothermal agent, copper sulfide (CuS), toll-like receptor-9 (TLR-9) agonist, cytosine-phospho-guanine oligodeoxynucleotides, and programmed death-ligand 1 (PD-L1) inhibitors (JQ1). Following NIR-II photoirradiation, CuS enabled the rapid elevation of localized temperature, achieving tumor ablation and induction of immunogenic cell death (ICD) as well as disruption of the lipid shell, enabling the precise release of two immune-therapeutical drugs in the tumor region. Combining ICD, TLR-9 stimulation, and inhibited expression of PD-L1 allows the subsequent enhancement of dendritic cell maturation and increases infiltration of cytotoxic T lymphocytes, facilitating regional antitumor immune responses. CONCLUSION: CNS nanoparticle-mediated photothermal-synergized immunotherapy efficiently suppressed the growth of primary and distant tumors in two mouse models and prevented pulmonary metastasis. This study thus provides a novel sight into photo-controllably safe and efficient immunotherapy.


Subject(s)
Immunotherapy/methods , Infrared Rays , Nanoparticles/chemistry , Neoplasms/therapy , Phototherapy/methods , Animals , Azepines/chemistry , Azepines/pharmacology , Azepines/therapeutic use , B7-H1 Antigen/antagonists & inhibitors , B7-H1 Antigen/metabolism , Cell Line, Tumor , Copper/chemistry , Dendritic Cells/cytology , Dendritic Cells/immunology , Dendritic Cells/metabolism , Humans , Immunogenic Cell Death/drug effects , Indocyanine Green/chemistry , Indocyanine Green/therapeutic use , Liposomes/chemistry , Mice , Mice, Inbred C57BL , Neoplasms/pathology , Toll-Like Receptor 9/metabolism , Transplantation, Heterologous , Triazoles/chemistry , Triazoles/pharmacology , Triazoles/therapeutic use
11.
Nutrients ; 13(11)2021 Nov 15.
Article in English | MEDLINE | ID: mdl-34836344

ABSTRACT

It has been previously demonstrated that KEKS food containing exogenous ketogenic supplement ketone salt (KS) and ketone ester (KE) decreased the lipopolysaccharide (LPS)-generated increase in SWD (spike-wave discharge) number in Wistar Albino Glaxo/Rijswijk (WAG/Rij) rats, likely through ketosis. KEKS-supplemented food-generated ketosis may increase adenosine levels, and may thus modulate both neuroinflammatory processes and epileptic activity through adenosine receptors (such as A1Rs and A2ARs). To determine whether these adenosine receptors are able to modify the KEKS food-generated alleviating effect on LPS-evoked increases in SWD number, an antagonist of A1R DPCPX (1,3-dipropyl-8-cyclopentylxanthine; 0.2 mg/kg) with LPS (50 µg/kg) and an antagonist of A2AR SCH58261 (7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine; 0.5 mg/kg) with LPS were co-injected intraperitoneally (i.p.) on the ninth day of KEKS food administration, and their influence not only on the SWD number, but also on blood glucose, R-beta-hydroxybutyrate (R-ßHB) levels, and body weight were measured. We showed that inhibition of A1Rs abolished the alleviating effect of KEKS food on LPS-generated increases in the SWD number, whereas blocking A2ARs did not significantly modify the KEKS food-generated beneficial effect. Our results suggest that the neuromodulatory benefits of KEKS-supplemented food on absence epileptic activity are mediated primarily through A1R, not A2AR.


Subject(s)
Dietary Supplements , Epilepsy, Absence/prevention & control , Ketones/administration & dosage , Pyrimidines/pharmacology , Triazoles/pharmacology , Xanthines/pharmacology , 3-Hydroxybutyric Acid/blood , Animals , Blood Glucose/drug effects , Body Weight/drug effects , Disease Models, Animal , Injections, Intraperitoneal , Ketosis/blood , Ketosis/drug therapy , Lipopolysaccharides/pharmacology , Purinergic P1 Receptor Antagonists , Rats , Rats, Wistar , Receptors, Purinergic P1/drug effects
12.
Sci Rep ; 11(1): 19223, 2021 09 28.
Article in English | MEDLINE | ID: mdl-34584169

ABSTRACT

Respiratory syncytial virus (RSV) is the primary cause of serious lower respiratory tract disease in infants, young children, the elderly and immunocompromised individuals. Therapy for RSV infections is limited to high risk infants and there are no safe and efficacious vaccines. Matrix (M) protein is a major RSV structural protein with a key role in virus assembly. Interestingly, M is localised to the nucleus early in infection and its export into the cytoplasm by the nuclear exporter, exportin-1 (XPO1) is essential for RSV assembly. We have shown previously that chemical inhibition of XPO1 function results in reduced RSV replication. In this study, we have investigated the anti-RSV efficacy of Selective Inhibitor of Nuclear Export (SINE) compounds, KPT-335 and KPT-185. Our data shows that therapeutic administration of the SINE compounds results in reduced RSV titre in human respiratory epithelial cell culture. Within 24 h of treatment, RSV replication and XPO1 expression was reduced, M protein was partially retained in the nucleus, and cell cycle progression was delayed. Notably, the effect of SINE compounds was reversible within 24 h after their removal. Our data show that reversible inhibition of XPO1 can disrupt RSV replication by affecting downstream pathways regulated by the nuclear exporter.


Subject(s)
Acrylates/pharmacology , Karyopherins/antagonists & inhibitors , Receptors, Cytoplasmic and Nuclear/antagonists & inhibitors , Respiratory Syncytial Virus Infections/drug therapy , Triazoles/pharmacology , Viral Matrix Proteins/metabolism , Virus Replication/drug effects , A549 Cells , Acrylates/therapeutic use , Cell Nucleus/metabolism , Drug Evaluation, Preclinical , Humans , Karyopherins/metabolism , Receptors, Cytoplasmic and Nuclear/metabolism , Respiratory Syncytial Virus Infections/virology , Respiratory Syncytial Virus, Human/drug effects , Respiratory Syncytial Virus, Human/metabolism , Triazoles/therapeutic use , Exportin 1 Protein
13.
Chem Biol Drug Des ; 98(5): 903-913, 2021 11.
Article in English | MEDLINE | ID: mdl-34480517

ABSTRACT

This work describes the synthesis, anti-Candida, and molecular modeling studies of eighteen new glucosyl-1,2,3-triazoles derived from eugenol and correlated phenols. The new compounds were characterized by combined Fourier Transform Infrared, 1 H and 13 C nuclear magnetic resonance and spectroscopy of high-resolution mass spectrometry. The synthesized compounds did not show significant cytotoxicity against healthy fibroblast human cells (MCR-5) providing interesting selectivity indexes (SI) to active compounds. Considering the antifungal activity, nine compounds showed anti-Candida potential and the peracetylated triazoles 17 and 18 were the most promising ones. Eugenol derivative 17 was active against three species of Candida at 26.1-52.1 µM. This compound was four times more potent than fluconazole against Candida krusei and less toxic (SI > 6.6) against the MCR-5 cells than fluconazole (SI > 3.3) considering this strain. Dihydroeugenol derivative 18 showed similar activity to 17 and was four times more potent and less toxic than fluconazole against C. krusei. The deacetylated glucosides and non-glucosylated corresponding derivatives did not show considerable antifungal action, suggesting that the acetyl groups are essential for their anti-Candida activity. Molecular docking coupled with molecular dynamics showed that 14α-lanosterol demethylase is a feasible molecular target, since 17 and 18 could bind to this enzyme once deacetylated in vivo, thereby acting as prodrugs. Also, these studies demonstrated the importance of hydrophobic substituents at the phenyl ring.


Subject(s)
Antifungal Agents/chemical synthesis , Eugenol/chemistry , Triazoles/chemical synthesis , Antifungal Agents/pharmacology , Apoptosis/drug effects , Candida/drug effects , Cell Survival/drug effects , Drug Evaluation, Preclinical , Fibroblasts/cytology , Humans , Molecular Docking Simulation , Molecular Dynamics Simulation , Structure-Activity Relationship , Triazoles/pharmacology
14.
Biochim Biophys Acta Mol Basis Dis ; 1867(12): 166267, 2021 12 01.
Article in English | MEDLINE | ID: mdl-34508829

ABSTRACT

Bromodomain and extraterminal (BET) proteins are promising therapeutic targets for hematological and solid tumors. However, BET inhibitor monotherapy did not show a significant therapeutic benefit for hepatocellular carcinoma (HCC) in preclinical trials. Here, we identified YAP/TAZ genes, as determinants for sensitivity to BET inhibitors. YAP/TAZ expression, especially TAZ, promote resistance to BET inhibitor. In addition, we analyzed that the mRNA level of PDE5 was positively correlated with YAP/TAZ based on TCGA database and demonstrated tadalafil, a PDE5 inhibitor, could block YAP/TAZ protein expression by activating Hippo pathway. Cotreatment with tadalafil and JQ-1 synergistically reduced YAP/TAZ protein expression, suppressed proliferation and induced G0-G1 arrest of cultured HCC cells. JQ-1 alone does not show significant benefits in a mouse model of HCC induced by c-Myc/N-Ras plasmids. In contrast, the combination, tadalafil and JQ-1, successfully suppressed tumor progression, enhanced antitumor immunity by improving the ratio of activated CD8 and extended the survival time of mice. Our data define the key role of YAP/TAZ in mediating resistance to BET inhibitor, described the PDE5/PKG/Hippo/YAP/TAZ axis and identified a common clinical drug that can be developed as an effective combined strategy to overcome BET inhibitor resistance in MYC/Ras-driven HCC.


Subject(s)
Carcinoma, Hepatocellular/drug therapy , Liver Neoplasms/drug therapy , Nerve Tissue Proteins/genetics , Receptors, Cell Surface/genetics , Tadalafil/pharmacology , YAP-Signaling Proteins/genetics , Animals , Azepines/pharmacology , Carcinoma, Hepatocellular/genetics , Carcinoma, Hepatocellular/pathology , Cyclic Nucleotide Phosphodiesterases, Type 5/genetics , Disease Models, Animal , Drug Resistance, Neoplasm/genetics , Drug Synergism , Gene Expression Regulation, Neoplastic/drug effects , Hippo Signaling Pathway/drug effects , Humans , Liver Neoplasms/genetics , Liver Neoplasms/pathology , Mice , Nerve Tissue Proteins/antagonists & inhibitors , Phosphodiesterase 5 Inhibitors/pharmacology , Proto-Oncogene Proteins c-myc/genetics , Receptors, Cell Surface/antagonists & inhibitors , Triazoles/pharmacology
15.
Int J Mol Sci ; 22(16)2021 Aug 13.
Article in English | MEDLINE | ID: mdl-34445398

ABSTRACT

Gibberellins (GAs) are an important group of phytohormones associated with diverse growth and developmental processes, including cell elongation, seed germination, and secondary growth. Recent genomic and genetic analyses have advanced our knowledge of GA signaling pathways and related genes in model plant species. However, functional genomics analyses of GA signaling pathways in Panax ginseng, a perennial herb, have rarely been carried out, despite its well-known economical and medicinal importance. Here, we conducted functional characterization of GA receptors and investigated their physiological roles in the secondary growth of P. ginseng storage roots. We found that the physiological and genetic functions of P. ginseng gibberellin-insensitive dwarf1s (PgGID1s) have been evolutionarily conserved. Additionally, the essential domains and residues in the primary protein structure for interaction with active GAs and DELLA proteins are well-conserved. Overexpression of PgGID1s in Arabidopsis completely restored the GA deficient phenotype of the Arabidopsis gid1a gid1c (atgid1a/c) double mutant. Exogenous GA treatment greatly enhanced the secondary growth of tap roots; however, paclobutrazol (PCZ), a GA biosynthetic inhibitor, reduced root growth in P. ginseng. Transcriptome profiling of P. ginseng roots revealed that GA-induced root secondary growth is closely associated with cell wall biogenesis, the cell cycle, the jasmonic acid (JA) response, and nitrate assimilation, suggesting that a transcriptional network regulate root secondary growth in P. ginseng. These results provide novel insights into the mechanism controlling secondary root growth in P. ginseng.


Subject(s)
Gene Expression Profiling/methods , Gibberellins/pharmacology , Panax/growth & development , Receptors, Cell Surface/genetics , Evolution, Molecular , Gene Expression Regulation, Developmental/drug effects , Gene Expression Regulation, Plant/drug effects , Loss of Function Mutation , Panax/genetics , Plant Proteins/genetics , Plant Roots/genetics , Plant Roots/growth & development , Protein Domains , Receptors, Cell Surface/chemistry , Sequence Analysis, RNA , Signal Transduction/drug effects , Triazoles/pharmacology
16.
J Pharmacol Exp Ther ; 379(1): 85-95, 2021 10.
Article in English | MEDLINE | ID: mdl-34253646

ABSTRACT

Current therapies for gastroparesis metoclopramide and domperidone carry risks of extrapyramidal symptoms and life-threatening cardiac arrhythmias. Trazpiroben, a novel, potent dopamine D2/D3 receptor antagonist, has low brain permeation and very low affinity for human ether-à-go-go-related gene (hERG) channel inhibition, potentially improving on safety profiles of existing therapies. Trazpiroben demonstrated the following receptor affinities: high for D2 and D3, moderate for D4, and minimal for D1 and D5 It demonstrated moderate affinity for adrenergic α 1B (α 1B) and 5-hydroxytryptamine (5HT) 2A receptors and low potential for off-target adverse events (AEs). Trazpiroben potently inhibited dopamine-activated D2L receptor activation of cognate G-proteins in human embryonic kidney 293 cell membranes and was a neutral D2L receptor antagonist. In vivo, trazpiroben dose-dependently increased prolactin release in orally dosed rat (0.1-1 mg/kg). Additionally, multiple oral doses in the rat (100 mg/kg) and dog (50 mg/kg) for 3 days produced robust plasma exposures and prolactin increases in both species. Trazpiroben inhibited retching/vomiting in the dog with apomorphine-induced emesis with a potency (0.1-1 mg/kg) like that of trazpiroben-mediated prolactin increases in rat. Oral trazpiroben (1, 10, and 30 mg/kg) did not affect rat rotarod performance, suggesting low brain penetration. Trazpiroben concentrations were low in cerebrospinal fluid versus plasma after multiple oral doses for 4 days in rat and dog. Trazpiroben weakly inhibited the hERG channel current (concentration causing half-maximal inhibition of control-specific binding of 15.6 µM), indicating little potential for disrupting cardiac rhythm. Overall, trazpiroben is a potent D2/D3 receptor antagonist designed to avoid the serious potential AEs associated with current gastroparesis therapies. SIGNIFICANCE STATEMENT: Trazpiroben is a novel, potent dopamine D2/D3 selective receptor antagonist designed to avoid adverse effects associated with the current pharmacological therapies metoclopramide and domperidone. Preclinical studies have demonstrated low brain penetration and weak affinity for the hERG channel, indicating that trazpiroben is not expected to be associated with central nervous system or cardiovascular safety issues. With these pharmacological properties, trazpiroben may represent a viable new treatment option for gastroparesis because of a potentially improved safety profile relative to existing therapies.


Subject(s)
Dopamine D2 Receptor Antagonists/therapeutic use , Gastroparesis/drug therapy , Receptors, Dopamine D3/antagonists & inhibitors , Triazoles/therapeutic use , Animals , Antiemetics/pharmacology , Antiemetics/therapeutic use , CHO Cells , Cricetinae , Cricetulus , Dogs , Domperidone/analogs & derivatives , Domperidone/pharmacology , Domperidone/therapeutic use , Dopamine Antagonists/chemistry , Dopamine Antagonists/pharmacology , Dopamine Antagonists/therapeutic use , Dopamine D2 Receptor Antagonists/chemistry , Dopamine D2 Receptor Antagonists/pharmacology , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical/methods , Female , HEK293 Cells , Humans , Male , Rats , Rats, Sprague-Dawley , Receptors, Dopamine D2/metabolism , Receptors, Dopamine D3/metabolism , Triazoles/pharmacology
17.
Int J Mol Sci ; 22(13)2021 Jul 05.
Article in English | MEDLINE | ID: mdl-34281290

ABSTRACT

Plasmodium falciparum's resistance to available antimalarial drugs highlights the need for the development of novel drugs. Pyrimidine de novo biosynthesis is a validated drug target for the prevention and treatment of malaria infection. P. falciparum dihydroorotate dehydrogenase (PfDHODH) catalyzes the oxidation of dihydroorotate to orotate and utilize ubiquinone as an electron acceptor in the fourth step of pyrimidine de novo biosynthesis. PfDHODH is targeted by the inhibitor DSM265, which binds to a hydrophobic pocket located at the N-terminus where ubiquinone binds, which is known to be structurally divergent from the mammalian orthologue. In this study, we screened 40,400 compounds from the Kyoto University chemical library against recombinant PfDHODH. These studies led to the identification of 3,4-dihydro-2H,6H-pyrimido[1,2-c][1,3]benzothiazin-6-imine and its derivatives as a new class of PfDHODH inhibitor. Moreover, the hit compounds identified in this study are selective for PfDHODH without inhibition of the human enzymes. Finally, this new scaffold of PfDHODH inhibitors showed growth inhibition activity against P. falciparum 3D7 with low toxicity to three human cell lines, providing a new starting point for antimalarial drug development.


Subject(s)
Antimalarials/pharmacology , Enzyme Inhibitors/pharmacology , Imines/pharmacology , Oxidoreductases Acting on CH-CH Group Donors/antagonists & inhibitors , Plasmodium falciparum/drug effects , Plasmodium falciparum/enzymology , Protozoan Proteins/antagonists & inhibitors , Pyrimidines/pharmacology , Animals , Antimalarials/chemistry , Antimalarials/toxicity , Cell Line , Dihydroorotate Dehydrogenase , Drug Evaluation, Preclinical , Enzyme Inhibitors/chemistry , Enzyme Inhibitors/toxicity , Humans , Imines/chemistry , Imines/toxicity , Plasmodium falciparum/growth & development , Pyrimidines/chemistry , Pyrimidines/toxicity , Recombinant Proteins/drug effects , Structure-Activity Relationship , Triazoles/pharmacology
18.
Exp Parasitol ; 226-227: 108123, 2021.
Article in English | MEDLINE | ID: mdl-34144040

ABSTRACT

The failures in the treatment of leishmaniasis is an increasing problem around the world, especially related to resistance. Thus, we describe the synthesis and in vivo anti-Leishmania activity of alkylphosphocholine and alkyltriazoles; besides, their likely action mechanisms stem from some eventual inhibition of parasite enzymes using computational tools. These compounds were tested in an in vivo hamster model infected with Leishmania Leishmania infantum chagasi. Fifty days after parasite inoculation, the two compounds 12-azidedodecylphosphocholine (3) and 3-(1-(12-fluorododecyl)-1H-1,2,3-triazol-1-yl)propano-1-ol (9), were separately administered once a day as oral suspensions (25 and 12.5 mg/kg/day, respectively) during ten days, and their efficacy was compared to the reference compound pentavalent antimonial Glucantime (GLU). Compound 3 significantly reduced the number of parasites in the spleen (4.93 × 102 amastigotes/g) and liver (4.52 × 103 amastigotes/g). Compound 9 reduced the number of amastigotes in the spleen to 1.30 × 104 and 1.36 × 103 amastigotes/g in the liver. GLU was the most effective overall treatment (7.50 × 101 and 2.28 × 102 amastigotes/g in the spleen and liver, respectively). The high activity levels of these compounds in vivo may stem from their high in vitro leishmanicidal activity and lipophilicity. The in silico absorption, distribution, metabolism, and excretion studies also showed some anti-Leishmania potential. Compound 9 had more lipophilic characteristics than those of compound 3. In silico studies of the nine enzymes of compounds 3 and 9 showed significant evidence of interactions with nicotimidase and tyrosine aminotransferase, demonstrating possible inhibition enzymes present in L. (L.) infantum chagasi. These compounds could be a promising template for developing a new class of leishmanicidal agents, by oral route, and deserve further investigation to explore different therapeutic regimens.


Subject(s)
Antiprotozoal Agents/pharmacology , Leishmania infantum/drug effects , Leishmaniasis, Visceral/drug therapy , Phosphorylcholine/pharmacology , Triazoles/pharmacology , Administration, Oral , Animals , Antiprotozoal Agents/administration & dosage , Antiprotozoal Agents/therapeutic use , Cricetinae , DNA, Complementary/biosynthesis , Female , Liver/chemistry , Mesocricetus , Molecular Docking Simulation , Phosphorylcholine/administration & dosage , Phosphorylcholine/chemistry , Phosphorylcholine/therapeutic use , RNA/isolation & purification , Spleen/chemistry , Triazoles/administration & dosage , Triazoles/chemistry , Triazoles/therapeutic use
20.
Plant Physiol Biochem ; 162: 547-555, 2021 May.
Article in English | MEDLINE | ID: mdl-33773230

ABSTRACT

Water deficit is the main reason for sugar yield losses in semi-arid areas. Triazole derivatives may mitigate the harmful impacts of water stress. Therefore, this study aimed to assess the effect of tebuconazole (TEB) application on antioxidants, root quality traits, and sugar yield under drought stress conditions. The treatments included three levels of irrigation set according to crop evapotranspiration (ETC): 100%, 75%, and 50% ETC, as well as three levels of TEB (0, 25, and 50 mg L-1). While significantly increasing antioxidant and alpha-amino-nitrogen (α-amino-N) contents, limited irrigation decreased total chlorophyll content, net photosynthesis rate, leaf relative water content, the weight of roots, and sugar yield. In contrast, TEB treatment resulted in a marked rise in all biological and physiological traits as well as enzymatic antioxidants. Our findings indicated that the decline in α-amino-N content might be linked to increased NR activity in response to the TEB application. Our results also showed that the stress-ameliorating role of TEB cannot be associated with the increase of flavonols (quercetin and rutin). Overall, the results demonstrated that TEB has a high potential for ameliorating the negative impacts of limited irrigation.


Subject(s)
Beta vulgaris , Oxidative Stress , Sugars , Triazoles/pharmacology , Water
SELECTION OF CITATIONS
SEARCH DETAIL